This post was originally published on this site
The London-listed company comprising health assets previously owned by GSK and Pfizer (NYSE:PFE) reported organic revenue growth of 9% last year.
The maker of Sensodyne toothpaste and Panadol painkillers had said in November that it expected an 8-8.5% increase in revenue last year.
